Semaglutide Pharmacokinetics Explored in Patients with Varying Renal Impairment

Understanding how kidney function affects drug metabolism and elimination is crucial for patient safety and efficacy, especially for medications used in chronic conditions like Type 2 Diabetes Mellitus. Patients with renal impairment often experience altered drug pharmacokinetics (PK), necessitating dose adjustments. This Phase 1 clinical trial specifically addresses how different degrees of renal impairment impact the pharmacokinetics of NN9535 (semaglutide).

While the detailed quantitative results for NN9535's pharmacokinetics (PK) across the different renal impairment groups are not provided in this summary, the study's primary aim was to precisely quantify these changes. The trial successfully enrolled 62 subjects, ensuring a robust dataset for analysis of how renal function impacts drug exposure. The completion of this Phase 1 study indicates that the necessary PK and safety data were collected to inform future dosing strategies. The study's design allowed for a comprehensive comparison of drug exposure in subjects with normal kidney function versus those with various degrees of impairment. The overarching finding, though specific data is absent from this summary, is that understanding the pharmacokinetic profile of NN9535 in renal impairment is essential for optimizing patient care and preventing potential adverse effects.